ERBB2 and breast cancer: To date, treatment decisions are taken based on the results of conventional histopathological and immunohistochemical analyses (ER, PR, HER2 and Ki67) identifying four main “surrogate” BC subgroups: luminal A, luminal B, Human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative BC (TNBC).